---
id: 047
title: Macrolides Spectrum and Mechanism
category: antimicrobials
subcategory: macrolides
tags: [macrolides, azithromycin, clarithromycin, erythromycin, atypicals, 50S-ribosome]
difficulty: medium
---

## Question

What is the spectrum of activity for macrolides (azithromycin, clarithromycin, erythromycin), and what is their mechanism of action? Use the **"CAPLS"** mnemonic for atypical coverage.

## Answer

### **Mechanism of Action:**
- Bind to **50S ribosomal subunit** (23S rRNA)
- Inhibit **transpeptidation and translocation** → block protein synthesis
- **Bacteriostatic** (bactericidal at high concentrations)

### **Spectrum of Activity (CAPLS for Atypicals):**

**CAPLS mnemonic for atypical coverage:**
- **C**hlamydophila (C. pneumoniae)
- **A**typical bacteria (broad)
- **P**ertussis (Bordetella pertussis)
- **L**egionella
- **S**pirochetes (some)

### **Complete Spectrum Table:**

| Organism Type | Activity | Notes |
|---------------|----------|-------|
| **Gram-positive** | Good | *S. pneumoniae*, *S. pyogenes*, viridans strep |
| ***S. aureus*** | Variable | MSSA only; MRSA resistant |
| **Atypicals** | Excellent | *Mycoplasma*, *Chlamydia*, *Legionella* |
| ***H. influenzae*** | Variable | Azithro > clarithro > erythro |
| ***Mycobacterium avium* (MAC)** | Good | Clarithro/azithro (not erythro) |
| **Anaerobes** | Poor | Better alternatives available |
| **Gram-negatives** | Poor | Except *H. influenzae*, *Moraxella* |

### **Macrolide Comparison:**

| Feature | Erythromycin | Clarithromycin | Azithromycin |
|---------|--------------|----------------|--------------|
| **Dosing** | QID | BID | Daily (QD) |
| **Acid stability** | Poor (food needed) | Good | Excellent |
| **GI side effects** | High (30-50%) | Moderate (15%) | Low (5-10%) |
| **CYP3A4 inhibition** | Strong | Strong | **Minimal** |
| **Half-life** | 1.5 hrs | 5 hrs | **68 hrs** (tissue) |
| **H. pylori** | No | **YES** | No |
| **MAC prophylaxis** | No | **YES** (CD4 <50) | **YES** (CD4 <50) |

## Key Points

### **Clinical Uses by Agent:**

**Azithromycin:**
- Community-acquired pneumonia (CAP)
- Chlamydia (1g × 1 dose)
- Pertussis prophylaxis
- Traveler's diarrhea (ETEC, Campylobacter)
- MAC prophylaxis (CD4 <50)

**Clarithromycin:**
- H. pylori eradication (triple therapy)
- MAC treatment (with ethambutol)
- CAP

**Erythromycin:**
- Gastroparesis (prokinetic effect)
- Pertussis treatment
- Rarely used for infections (GI side effects)

### **Resistance Mechanisms:**
- **Target modification:** Methylation of 23S rRNA (*ermB* gene) → MLSB resistance
- **Efflux pumps:** *mef* genes
- **Ribosomal mutations:** Point mutations in 23S rRNA

### **Cross-Resistance:**
- **MLSB resistance** affects macrolides, lincosamides (clindamycin), streptogramins (quinupristin-dalfopristin)

## Sources

- [StatPearls NBK551495: Macrolides]
- [PMC2015000: Macrolide CYP3A4 Drug Interactions]
- [PMC5346035: Macrolide PK/PD Pathway]

## Media

N/A
